Kabra毒品公司(Kabra Defines)在Q3 FY26 26 中利润上涨了578%,扭转了损失,并计划在200%的库存增加的情况下扩张。 Kabra Drugs posted a 578% profit surge in Q3 FY26, reversed a loss, and plans expansion amid a 200% stock rise.

总部位于金奈的微型股公司Kabra Drugs Limited报告称，截至2025年12月31日的2026财年第三季度税后利润同比增长578%，达到2.56亿卢比，扭转了去年同期的亏损。 Kabra Drugs Limited, a Chennai-based microcap company, reported a 578% year-on-year increase in profit after tax to ₹2.56 crore for Q3 FY26, ending December 31, 2025, reversing a prior-year loss. 收入升至30.42亿,季度增长53.9%,并从2024年12月的零收入恢复. Revenue jumped to ₹30.42 crore, a 53.9% quarter-on-quarter rise and a recovery from zero revenue in December 2024. 该公司计划进入医疗设备制造厂,与MR Francise合伙增加200个频道伙伴,并在批准前更改名称。 The company plans to enter medical equipment manufacturing, partner with MR Franchise to add 200 channel partners, and change its name, pending approvals. 根据SEBI条例对财务情况进行了审查,去年股票增长了近200%。 Financials were reviewed per SEBI regulations, and the stock has risen nearly 200% in the past year. 前瞻性说明包括关于未来业绩的风险和免责声明。 Forward-looking statements include risks and disclaimers about future performance.